Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 10/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.51 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | CCKAR | P32238 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14544900 | 1.00 | HMGCR (0.52) | HMGCRCYP2C9SIRT6ABCC3ABCB11 | |
| SCHEMBL4020685 | 1.00 | HMGCR (0.52) | HMGCRCYP2C9SIRT6ABCC3ABCB11 | |
| SCHEMBL4901682 | 1.00 | HMGCR (0.52) | HMGCRCYP2C9SIRT6ABCC3ABCB11 | |
| SCHEMBL4901679 | 1.00 | HMGCR (0.52) | HMGCRCYP2C9SIRT6ABCC3ABCB11 | |
| SCHEMBL9274196 | 1.00 | HMGCR (0.52) | HMGCRCYP2C9SIRT6ABCC3ABCB11 | |
| SCHEMBL16476432 | 0.92 | HMGCR (0.43) | HMGCR | |
| SCHEMBL9763505 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL1660810 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL9763539 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL5597970 | 0.91 | HMGCR (0.52) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2021-06-10 | — | — | US | disclosed |
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2021-06-10 | — | — | US | disclosed |
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2019-02-07 | — | — | US | disclosed |
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2019-02-07 | — | — | US | disclosed |
| WO-2017137469-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2017-08-17 | — | — | WO | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| EP-1472228-B1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | NOVARTIS AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080182873-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | ACEMOGLU MURAT | 2008-07-31 | — | — | US | disclosed |
| US-20080182873-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | ACEMOGLU MURAT | 2008-07-31 | — | — | US | disclosed |
| US-7371865-B2 | Process for the manufacture of HMG-CoA reductase inhibitors | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371865-B2 | Process for the manufacture of HMG-CoA reductase inhibitors | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371865-B2 | Process for the manufacture of HMG-CoA reductase inhibitors | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| US-20050070605-A1 | Process for the manufacture of hmg-coa reductase inhibitors | ACEMOGLU MURAT (CH) | 2005-03-31 | — | — | US | disclosed |
| EP-0379917-B1 | Optically active (meth)acrylic-acid derivatives, their preparation, their polymerisation into optically active polymers and their use | BAYER AG (DE) | 1995-08-09 | — | — | EP | disclosed |
| US-5274167-A | A N-(meth)acryloyl amino acid amide | BAYER AKTIENGESELLSCHAFT (DE) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182873-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | HMGCR, COASY, DHCR7 | HMGCR 1/4885CYP2C9 155/4885SIRT6 429/4885 |
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | FABP3, TNNI3, TNNT2 | HMGCR 18/4885CYP2C9 4386/4885SIRT6 166/4885 |
| US-20080039625-A1 | Screening Methods | CBR3, ZKSCAN2, CRBN | HMGCR 980/4885CYP2C9 26/4885SIRT6 2321/4885 |
| US-20050070605-A1 | Process for the manufacture of hmg-coa reductase inhibitors | HMGCR, COASY, DHCR7 | HMGCR 1/4885CYP2C9 155/4885SIRT6 429/4885 |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | HMGCR 105/4885CYP2C9 1928/4885SIRT6 703/4885 |
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | FABP3, TNNI3, TNNT2 | HMGCR 16/4885CYP2C9 4070/4885SIRT6 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.